Research & Education
CURE Expert Connections
Email Sign Up
To start your customized experience click the start button
Customize your homepage by selecting specific cancer types.
Cancer of Unknown Primary
Diet and Exercise
Gastrointestinal stromal tumor
General Financial Topics
General Psychosocial Aspect Topics
Head & Neck Cancer
Mantle Cell Lymphoma
Metastatic Breast Cancer
Side Effect Management
Small Lymphocytic Lymphoma (SLL)
Advocacy & Research
Share Your Story
Newsletter Sign Up
Ovarian Cancer Heroes
Bone Health Champions
Terms & Conditions
Cure Media Group, LLC.
2 Clarke Drive
Cranbury, NJ 08512
Copyright © 2018
CURE Media Group.
All rights reserved.
Cure Media Group, LLC. All Rights Reserved.
CURE does not provide medical, diagnostic, or treatment advice.
Distress Levels High Among Patients With Common Form of Kidney Cancer
Many patients with renal cell carcinoma, the most common type of kidney cancer, experience high levels of distress, according to study findings published in
A State of Flux for Kidney Cancer
DEBORAH ABRAMS KAPLAN
Targeted drugs are controversial in early-stage kidney cancer, but play a more important role in treating advanced disease.
Germline Mutations in Non-Clear Cell Renal Cell Carcinoma May Direct Systemic Therapy
More than 20 percent of patients with non–clear cell renal cell carcinoma (RCC) had a germline mutation, of which half had the potential to direct systemic therapy.
New Approach May Spare Some with Kidney Cancer from Undergoing Surgery
Experts at Roswell Park Comprehensive Cancer Center discovered a way to assess if a kidney tumor is benign or malignant, potentially sparing many from having to undergo surgery.
NCCN Updates Guidelines for Kidney Cancer
Kristie L. Kahl
The National Comprehensive Cancer Network updated its Clinical Practice Guidelines to add two new options for the frontline treatment of patients with kidney cancer.
Immunotherapy Researchers Win Nobel Prize
Immunotherapy pioneers James P. Allison, Ph.D., and Tasuku Honjo, M.D., Ph.D., have won the 2018 Nobel Prize in Physiology or Medicine for their research that eventually led to the use of immune checkpoint inhibitors to treat cancer.
The Future of Kidney Cancer Management
Sandy Liu, MD, reviews the current challenges and recent advances in the treatment of renal cell carcinoma, or kidney cancer, as well as what she looks most forward to in the coming years.
Practical Advice for Patients With Kidney Cancer
Sandy Liu, MD, offers practical advice for patients undergoing treatment for renal cell carcinoma, or kidney cancer, regarding self-education, self-advocacy and adherence to therapy.
Second-Line Therapeutic Options for Kidney Cancer
Sandy Liu, MD, outlines the available second-line therapeutic options for renal cell carcinoma, or kidney cancer, as well as what factors she considers when selecting from agents in this setting.
First-Line Kidney Cancer Treatment: Targeted Therapy
Sandy Liu, MD, reflects on the value of targeted agents in the first-line treatment setting of renal cell carcinoma, or kidney cancer, given clinical and personal experience.
Not a member?
Sign up now!
Continue without login
OPTIONAL INFORMATION: The following information helps us tailor CURE to fit your needs
Please type below what best describes your interests and click on the selection(s):
I am a:
Please list other: